Premium
Effects of Long‐Term Treatment with Probucol on Serum Lipoproteins in Cases of Familial Hypercholesterolemia in the Elderly
Author(s) -
Morisaki Nobuhiro,
Mori Seijiro,
Kobayashi Junji,
Ishikawa Yo,
Shinomiya Masaki,
Shirai Kohji,
Saito Yasushi,
Yoshida Sho
Publication year - 1990
Publication title -
journal of the american geriatrics society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.992
H-Index - 232
eISSN - 1532-5415
pISSN - 0002-8614
DOI - 10.1111/j.1532-5415.1990.tb01590.x
Subject(s) - probucol , medicine , familial hypercholesterolemia , endocrinology , apolipoprotein b , lipoprotein , low density lipoprotein , cholesterol
The effect of probucol in lowering serum lipoprotein in young and middle‐aged (YM) and elderly (E) patients with familial hypercholesterolemia were compared. Probucol at 1000 mg/day was administered orally to 37 YM patients and 14 E patients for an average of 10 months. Probucol treatment for this period caused significant reductions in the serum levels of total cholesterol, low density lipoprotein cholesterol (LDL‐C), high density lipoprotein cholesterol, and apoprotein AI, AII, B, and CIII in both groups. The decreases in the levels of total cholesterol, LDL‐C, and apoprotein B were greater in the E group than in the YM group (total cholesterol: YM, −19.3%, E, −31.3% [P < .001]; LDL‐C: YM −17.0%, E, −35.4% [P < .001]; apoprotein B: YM, −12.3%, E, −28.1% [P < .01]). The decreases in other parameters in the two groups were not significantly different. The serum probucol concentrations in the YM and E groups were not significantly different. No significant side effects were observed in any patient. Thus probucol reduced the serum level of LDL more in the E group than in the YM group, and did so without any increase in the serum concentration of the drug or in side effects, suggesting that probucol is safe and beneficial for use in elderly patients.